Back to search

Italy· 050465018

ELADYNOS*1 penna 1,5 ml 2 mg/ml

A abaloparatide product containing abaloparatide, registered in Italy by THERAMEX IRELAND LIMITED, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC H05AA04

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedELADYNOS*1 penna 1,5 ml 2 mg/mlATCH05AA04REGISTER NO.050465018PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Abaloparatide is registered in 12 of 19 countries.

Countries holding a registration under ATC H05AA04 (abaloparatide), each read from that country’s own register.

  • This record: Italy
  • 8 of them publish a price we can compare per daily dose

Abaloparatide · ATC H05AA04

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Active substance
Abaloparatide
Manufacturer
THERAMEX IRELAND LIMITED
Country
Italy (IT)
ATC code
H05AA04
ATC class
Abaloparatide
Defined daily dose
80 mcg, P
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    050465018
    ELADYNOS*1 penna 1,5 ml 2 mg/ml
    EUR 330.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for abaloparatide.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Abaloparatide · interactions on record

2 records

  • 2 moderate

Most severe, free to view

  • CalcipotriolD05AX02moderate
  • CalcitriolD05AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f5571a5b-1c85-437d-a195-87f412a6fe03
GET /v1/drugs/f5571a5b-1c85-437d-a195-87f412a6fe03?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 330.55,
  "source": "aifa",
  "currency": "EUR",
  "strength": "ABALOPARATIDE 3MG/1,5ML 1 UNITA' USO PARENTERALE",
  "substance": "Abaloparatide",
  "equivalence_group": "NQO",
  "transparency_flag": null
}

See everything about abaloparatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.